GLP-1 Receptor Agonist Market Size

GLP-1 Receptor Agonist Market Size

The global GLP-1 receptor agonist market size was valued at USD 24.4 billion in 2023 and is expected to grow at 9.7% CAGR from 2024 to 2032, driven by rising incidences of type 2 diabetes and obesity globally. A study published in The Lancet in June 2023 reveals that over half a billion people globally are living with diabetes, impacting individuals of all ages and genders in every country. This number is expected to more than double, reaching 1.3 billion within the next 30 years.

To get key market trends

  Download Free Sample

With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM). As more patients and healthcare providers seek effective diabetes management solutions with minimal side effects, demand for GLP-1 receptor agonists is set to surge. These drugs, which mimic the activity of natural incretin hormones, help control blood sugar levels while also promoting weight loss, making them a crucial option for diabetic and obese populations. With these health benefits and advancements in drug formulations, the market is expected to experience substantial growth.
 

The market is poised for significant growth due to the increasing prevalence of type 2 diabetes, rising obesity rates, and growing awareness of GLP-1 receptor agonists’ effectiveness in glycemic control and weight management. The World Obesity Atlas 2023 projects that by 2035, over 4 billion people globally could be classified as overweight or obese, a sharp increase from 2.6 billion in 2020. This would mean that over 50% of the world’s population—up from 38% in 2020—could be affected, excluding children under five. Additionally, obesity rates alone are expected to increase from 14% to 24% within this timeframe, potentially impacting nearly 2 billion adults, adolescents, and children by 2035.
 

However, the high cost of GLP-1 receptor agonists and limited access to these therapies in certain regions may act as restraining factors. The market's reliance on innovative drug formulations that can improve patient compliance is a strong growth driver, especially as several leading pharmaceutical companies invest heavily in research and development. Despite the benefits of GLP-1 receptor agonists, affordability and insurance coverage limitations remain critical barriers in some regions, which could potentially hinder widespread adoption.